Compassionate Use of Midostaurin in Myeloid and Lymphoid Neoplasia with FGFR1 Abnormality

Abstract

Background: Patients with stem cell myeloproliferative disorders have a particularly poor prognosis and limited treatment options, i.e. mainly aggressive chemotherapy or allogeneic stem cell transplantation. In 2004, Chen et al. reported a patient presenting a t(8;13) (p11;q12) cytogenic anomaly who responded positively to treatment with PKC412 (midostaurin… (More)

Topics

3 Figures and Tables

Cite this paper

@inproceedings{Beris2014CompassionateUO, title={Compassionate Use of Midostaurin in Myeloid and Lymphoid Neoplasia with FGFR1 Abnormality}, author={Photis Beris and Monika Nagy and Daniel W. Robert and Kaveh Samii and Tom McKee and Jovita Schuler}, year={2014} }